Quick Answer
Tango Therapeutics, Inc. reported Total Revenue of $62.38 million for fiscal year 2025.
Tango Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $62.38M | +48.3% |
| 2024 | $42.07M | +15.2% |
| 2023 | $36.53M | +46.9% |
| 2022 | $24.86M | -32.9% |
| 2021 | $37.04M | +383.8% |
| 2020 | $7.66M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $53.81M | +363.6% | +1591.6% |
| June 30, 2025 | $3.18M | -84.0% | -41.0% |
| March 31, 2025 | $5.39M | -16.7% | -53.5% |
| September 30, 2024 | $11.61M | +8.2% | -41.6% |
| June 30, 2024 | $19.88M | +36.1% | +207.1% |
| March 31, 2024 | $6.47M | +12.2% | -39.7% |
| September 30, 2023 | $10.73M | +55.1% | -26.5% |
| June 30, 2023 | $14.60M | +153.0% | +153.2% |
- Tango Therapeutics, Inc. showed an increase of +48.3% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2025 period, Tango Therapeutics, Inc.’s total revenue has grown by 714.8% (from $7.66 million to $62.38 million).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: